Clinical trial NCT02922738: The Impact of a Dermatology Information Source on Skin Problem Outcomes in Primary Care
Official title: The Impact of a Dermatology Information Source on Skin Problem Outcomes in Primary Care
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Decision Support Systems,Clinical
Skin Diseases
Keywords: Clinical Knowledge Systems, Decision support, Dermatology
Technology Assessment
Lead sponsor: University of Vermont
Sponsor class: OTHER
Collaborators: name: University of Vermont Medical Center
First posted: 2016-10-04
Enrollment: 465
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Health care providers use a variety of computerized medical information sources to reduce knowledge gaps and support patient care decisions. Few studies have evaluated the impact of medical information sources on patient outcomes. Skin problems are the reason for many visits to primary care providers and result in a high percentage of referrals to dermatologists and return visits to primary care for the same skin problem.

The objective is to evaluate the impact of primary care providers' use of a dermatology information source, VisualDx, on skin problems outcomes.

The study design is a cluster-randomized controlled trial. Participants include primary care providers as clusters and their patients with skin problems. Providers are randomized to intervention group that refers to VisualDx when seeing a patient with a skin problem, or to the control group who does not. Patients have the randomized group status of the doctor they saw for the problem.

Patients are interviewed to determine the problem status and how many follow-up visits they had for the problem at intervals after the index visit.

Detailed description: The research design is a cluster randomized controlled trial of a computerized dermatology information source. This is a two-level design in which primary care providers (PCPs) who see patients for skin problems are the subjects of randomization. Their patients are the subjects of the data collection and analysis. The cluster design examines how much variation in the outcomes is attributable to the providers, how much to patients within the clusters, and how much to the intervention information source itself.

Provider Level:

After completing a baseline questionnaire, providers are randomized to intervention or control groups. Intervention group providers have an orientation to the study protocol that includes how to access and use VisualDx. Control providers receive the protocol overview, but no orientation to the intervention.

Intervention providers agree to refer to VisualDx content when they have a patient with a skin complaint. Control group providers agree not use VisualDx as a reference but may use another medical information source or none.

Patient Level:

To identify eligible patients, authorized investigators reviewed information from the patient record sufficient to send a letter to them over the provider's signature to notify them about the study. The letter gives the option to refuse any contact.

At 30 days after the primary care visit, a study team investigator phones each eligible patients, explains the study, and obtains verbal consent. The investigators are blinded to the randomized group status of the patients.

The investigator proceeds with the interview questionnaire on consent. Age, sex is collected. Patients are asked whether the skin problem is resolved ("Is it all better?"). For every resolved problem, we ask when (date or days since visit) it was resolved. We also ask how many return visits the patient has had with any provider for that problem.

If not resolved, the patient is called again at 60 days and asked the same questions. If not resolved then, we call the patient again at 90 days. The last call to any patient is at 90 days from the index visit for the problem.

Data Analysis and Statistical Measures

The primary predictor variable for both aims is the use of the VisualDx information source by the primary care provider.

For the "days to resolution" outcome variable, the time unit (days) and the status of the problem after 90 days (resolved or not resolved) will be evaluated for each group with Kaplan-Meier survival analysis and the non-parametric log rank test of significance.

For the "number of follow-up visits" outcome variable, the binary predictor (intervention group) and discrete outcome variable (number of visits) will be evaluated with Wilcoxon-rank sum test for non-normal data. The first visit of a patient to a participating provider for a skin problem is considered the index visit and that provider considered the index provider regardless of the provider seen on any subsequent appointment. Analysis will adhere to the intention-to-treat principle with group assignment determined by randomization regardless of whether VisualDx was deployed for care or not. Problems unresolved at the last contact will be censored as unresolved for the Kaplan-Meier analysis.

For aim 1, the estimated sample size to detect an average difference of 8 days in time to resolution with a standard deviation of 20 and an intra-cluster correlation (ICC) of 0.025. With alpha .05 and beta .80, the study would need a minimum 26 providers enrolled with an average 10 patient participants in each provider's cluster for a total of 286 participants completing the study. We planned to enroll at least 30 providers and up to 500 patients to insure against loss to follow-up of, increased standard deviation, or larger than anticipated Intra-Cluster Correlation.

Eligibility criteria: Inclusion Criteria:

* Patients seen by a participating Primary Care Provider for a chronic or acute skin problem

Exclusion Criteria:

* Skin problems due to burns or lacerations
* Cognitively impaired, mentally ill, prisoners, non-English speaking

Primary outcomes:
measure: Number of Patients With Resolved Skin Problems
timeFrame: Period of assessment was up to 3 months (90 days) after index visit.
measure: Number of Follow-Up Visits to Any Provider for the Same Problem
timeFrame: Period of Assessment is up to 90 days after index visit
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Vermont
name: Marianne D Burke, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Vermont
name: Benjamin Littenberg, MD
role: STUDY_CHAIR
References:
citation: Alper BS, White DS, Ge B. Physicians answer more clinical questions and change clinical decisions more often with synthesized evidence: a randomized trial in primary care. Ann Fam Med. 2005 Nov-Dec;3(6):507-13. doi: 10.1370/afm.370.
citation: Del Fiol G, Haug PJ, Cimino JJ, Narus SP, Norlin C, Mitchell JA. Effectiveness of topic-specific infobuttons: a randomized controlled trial. J Am Med Inform Assoc. 2008 Nov-Dec;15(6):752-9. doi: 10.1197/jamia.M2725. Epub 2008 Aug 28.
citation: Marshall JG, Sollenberger J, Easterby-Gannett S, Morgan LK, Klem ML, Cavanaugh SK, Oliver KB, Thompson CA, Romanosky N, Hunter S. The value of library and information services in patient care: results of a multisite study. J Med Libr Assoc. 2013 Jan;101(1):38-46. doi: 10.3163/1536-5050.101.1.007.
citation: Isaac T, Zheng J, Jha A. Use of UpToDate and outcomes in US hospitals. J Hosp Med. 2012 Feb;7(2):85-90. doi: 10.1002/jhm.944. Epub 2011 Nov 16.
citation: Awadalla F, Rosenbaum DA, Camacho F, Fleischer AB Jr, Feldman SR. Dermatologic disease in family medicine. Fam Med. 2008 Jul-Aug;40(7):507-11.
citation: Federman DG, Reid M, Feldman SR, Greenhoe J, Kirsner RS. The primary care provider and the care of skin disease: the patient's perspective. Arch Dermatol. 2001 Jan;137(1):25-9. doi: 10.1001/archderm.137.1.25.